LithiumvanadatesLiV_(3)O_(8)-LiV_(6)O_(15)(LVO)witha heterojunction structure are synthesized using a conventional high-temperature solid-state method to address the challenges of low ionic conductivity,rapid capacity...LithiumvanadatesLiV_(3)O_(8)-LiV_(6)O_(15)(LVO)witha heterojunction structure are synthesized using a conventional high-temperature solid-state method to address the challenges of low ionic conductivity,rapid capacity decay,and poor cycling performance in conventional lithium-ion battery cathode materials.The charge-discharge processes of LVO span multiple platforms,delivering an impressive specific discharge capacity of 219.4 mAh.g^(-1) at 1C.Remarkably,LVO exhibits a high-capacity retention rate of 81.3%after 800 cycles within the typical operating voltage range of lithium-ion batteries(2.8-4.3V).Rate capability tests and electrochemical impedance spectroscopy(EIS)reveal that,compared to traditional cathode materials,LVO significantly enhances Li*diffusion rates(D_(Li*))and reduces charge transfer resistance(Ret).展开更多
Non-alcoholic fatty liver disease(NAFLD) is an important health problem worldwide. NAFLD encompasses a histological spectrum ranging from bland liver steatosis to severe steatohepatitis(nonalcoholic steatohepatitis, N...Non-alcoholic fatty liver disease(NAFLD) is an important health problem worldwide. NAFLD encompasses a histological spectrum ranging from bland liver steatosis to severe steatohepatitis(nonalcoholic steatohepatitis, NASH) with the potential of progressing to cirrhosis and its associated morbidity and mortality. NAFLD is thought to be the hepatic manifestation of insulin resistance(or the metabolic syndrome); its prevalence is increasing worldwide in parallel with the obesity epidemic. In many developed countries, NAFLD is the most common cause of liver disease and NASH related cirrhosis is currently the third most common indication for liver transplantation. NASH related cirrhosis is anticipated to become the leading indication for liver transplantation within the next one or two decades. In this review, we discuss how liver transplantation is affected by NAFLD, specifically the following:(1) the increasing need for liver transplantation due to NASH;(2) the impact of the increasing prevalence of NAFLD in the general population on the quality of deceased and live donor livers available for transplantation;(3) the long term graft and patient outcomes after liver transplantation forNASH,and finally;and(4)the de novo occurrence of NAFLD/NASH after liver transplantation and its impact on graft and patient outcomes.展开更多
基金supported by the National Natural Science Foundation of China(Nos.52125405 and U22A20108)Thailand Science Research and Innovation Fund Chulalongkorn University,National Research Council of Thailand(NRCT)+1 种基金Chulalongkorn University(No.42A660383)the Hub of Talents:Sustainable Materials for Circular Economy,National Research Council of Thailand(NRCT).
文摘LithiumvanadatesLiV_(3)O_(8)-LiV_(6)O_(15)(LVO)witha heterojunction structure are synthesized using a conventional high-temperature solid-state method to address the challenges of low ionic conductivity,rapid capacity decay,and poor cycling performance in conventional lithium-ion battery cathode materials.The charge-discharge processes of LVO span multiple platforms,delivering an impressive specific discharge capacity of 219.4 mAh.g^(-1) at 1C.Remarkably,LVO exhibits a high-capacity retention rate of 81.3%after 800 cycles within the typical operating voltage range of lithium-ion batteries(2.8-4.3V).Rate capability tests and electrochemical impedance spectroscopy(EIS)reveal that,compared to traditional cathode materials,LVO significantly enhances Li*diffusion rates(D_(Li*))and reduces charge transfer resistance(Ret).
文摘Non-alcoholic fatty liver disease(NAFLD) is an important health problem worldwide. NAFLD encompasses a histological spectrum ranging from bland liver steatosis to severe steatohepatitis(nonalcoholic steatohepatitis, NASH) with the potential of progressing to cirrhosis and its associated morbidity and mortality. NAFLD is thought to be the hepatic manifestation of insulin resistance(or the metabolic syndrome); its prevalence is increasing worldwide in parallel with the obesity epidemic. In many developed countries, NAFLD is the most common cause of liver disease and NASH related cirrhosis is currently the third most common indication for liver transplantation. NASH related cirrhosis is anticipated to become the leading indication for liver transplantation within the next one or two decades. In this review, we discuss how liver transplantation is affected by NAFLD, specifically the following:(1) the increasing need for liver transplantation due to NASH;(2) the impact of the increasing prevalence of NAFLD in the general population on the quality of deceased and live donor livers available for transplantation;(3) the long term graft and patient outcomes after liver transplantation forNASH,and finally;and(4)the de novo occurrence of NAFLD/NASH after liver transplantation and its impact on graft and patient outcomes.
